Page last updated: 2024-11-13
capilliposide b
Description
capilliposide B: from Lysimachia capillipes; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
capilliposide B : A triterpenoid saponin that consists of anagalligenin A substituted by a caproyl group at position 22 and a beta-D-xylopyranosyl-(1->2)-beta-D-glucopyranosyl-(1->4)-[beta-D-glucopyranosyl-(1->2)]-alpha-L-arabinopyranosyl moiety at position 3 via a glycosidic linkage. It is isolated from the whole plants of Lysimachia capillipes and has been shown to exhibit potent cytotoxicity against human A-2780 cells. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Lysimachia | genus | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
| Lysimachia capillipes | species | [no description available] | Primulaceae | A plant family of the order ERICALES, class MAGNOLIOPSIDA, with flowers having both stamens and pistil, producing encapsulated fruits.[MeSH] |
Cross-References
Synonyms (5)
| Synonym |
|---|
| capilliposide b |
| 22-caproylanagalligenin a-3-o-beta-d-xylopyranosyl-(1->2)-beta-d-glucopyranosyl-(1->4)-[beta-d-glucopyranosyl-(1->2)]-alpha-l-arabinopyranoside |
| (3beta,16alpha,22alpha)-3-{[beta-d-glucopyranosyl-(1->2)-[beta-d-xylopyranosyl-(1->2)-beta-d-glucopyranosyl-(1->4)]-alpha-l-arabinopyranosyl]oxy}-16,28-dihydroxy-13,28-epoxyoleanan-22-yl hexanoate |
| CHEBI:65574 |
| Q27134030 |
Roles (2)
| Role | Description |
|---|
| antineoplastic agent | A substance that inhibits or prevents the proliferation of neoplasms. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (10)
| Class | Description |
|---|
| tetrasaccharide derivative | An oligosaccharide derivative that is formally obtained from a tetrasaccharide. |
| hexacyclic triterpenoid | A triterpenoid that consists of a hexacyclic ring system. |
| bridged compound | A polycyclic compound in which two rings have two or more atoms in common. |
| lactol | Cyclic hemiacetals formed by intramolecular addition of a hydroxy group to an aldehydic or ketonic carbonyl group. They are thus 1-oxacycloalkan-2-ols or unsaturated analogues. |
| alpha-L-arabinopyranoside | |
| cyclic ether | Any ether in which the oxygen atom forms part of a ring. |
| diol | A compound that contains two hydroxy groups, generally assumed to be, but not necessarily, alcoholic. Aliphatic diols are also called glycols. |
| secondary alcohol | A secondary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has two other carbon atoms attached to it. |
| triterpenoid saponin | A terpene glycoside in which the terpene moiety is a triterpenoid. |
| hexanoate ester | Any fatty acid ester where the carboxylic acid component is hexanoic (also known as caproic) acid. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 2 (28.57) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 13.09
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 13.09 (24.57) | | Research Supply Index | 2.08 (2.92) | | Research Growth Index | 5.17 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |